LLY
Eli Lilly and Company
LLY has the edge over RGEN overall, supported by stronger fundamentals and stronger valuation.
RGEN
Repligen Corporation
RGEN trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
RGEN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
RGEN's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
RGEN PE Valuation
RGEN has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over RGEN on the outlook, with more favorable profitability expectations.
RGEN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for RGEN, but weaker profitability.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus RGEN up 38%.
RGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.43 | -16% |
| Q3 2022 | $2.90 | +38% |
| Q2 2022 | $2.77 | +55% |
| Q1 2022 | $2.53 | +74% |
| Q4 2021 | $2.24 | +102% |
| Q3 2021 | $2.10 | +156% |
| Q2 2021 | $1.79 | +209% |
| Q1 2021 | $1.45 | +222% |
| Q4 2020 | $1.11 | +152% |
RGEN's earnings per share have climbed steadily: $2.90 over the past year, up 38% from the year before, and higher year over year every quarter since late 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over RGEN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over RGEN on profitability, with a higher operating margin.
RGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $209.3M | +11% |
| Q2 2026 | $204.1M | +12% |
| Q1 2026 | $194.3M | +15% |
| Q4 2025 | $197.9M | +18% |
| Q3 2025 | $188.8M | +22% |
| Q2 2025 | $182.4M | +15% |
| Q1 2025 | $169.2M | +10% |
| Q4 2024 | $167.5M | +0.6% |
RGEN's revenue has grown year over year for nine quarters in a row: $209M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -14% | -23 points |
| Q2 2026 | 6.8% | -0.8 points |
| Q1 2026 | 8.2% | +4.3 points |
| Q4 2025 | 9% | +31 points |
| Q3 2025 | 8.9% | +14 points |
| Q2 2025 | 7.6% | +4.2 points |
| Q1 2025 | 3.9% | +1.4 points |
| Q4 2024 | -22% | -28 points |
RGEN's operating margin was −14% last quarter, down 23 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over RGEN on cash flow, with more consistent year-over-year improvement.
RGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $38.2M | -12% |
| Q2 2026 | $27.4M | +28% |
| Q1 2026 | $23.6M | +106% |
| Q4 2025 | $17.6M | -48% |
| Q3 2025 | $43.4M | +2.5% |
| Q2 2025 | $21.5M | -42% |
| Q1 2025 | $11.4M | -69% |
| Q4 2024 | $33.6M | +87% |
RGEN generated $107M in free cash flow over the past year, down 3% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
RGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -80K shares |
| 1 year | -1.4% | -810K shares |
RGEN has the edge over LLY on shareholder dilution, with a more favorable share count trend.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
RGEN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.8x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | -2.7x | Net Cash |
| Q2 2025 | -14.0x | Net Cash |
| Q1 2025 | -17.8x | Net Cash |
| Q4 2024 | -21.9x | Net Cash |
RGEN has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
RGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.2 | Neutral |
| Stochastic | 48.9 | Neutral |
RGEN's weekly RSI is 53 (neutral) and its Stochastic is 49 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
RGEN PE vs Healthcare Sector
| Metric | RGEN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RGEN has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over RGEN on trend strength, trading above more of its moving averages.
RGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $176.8 | 5.8% below |
| 20 week MA | $166.0 | 0.3% above |
| 50 week MA | $147.6 | 13% above |
| 100 week MA | $142.8 | 17% above |
| 200 week MA | $152.1 | 9.5% above |
RGEN has slipped below its 8-week average, but it's still above the other four, and 9.5% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over RGEN on returns for 2026, with the stronger performance.
RGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $92.2 | $195.7 | +112% |
| 2021 | $195.7 | $264.7 | +35% |
| 2022 | $264.7 | $167.5 | -37% |
| 2023 | $167.5 | $179.8 | +7.3% |
| 2024 | $179.8 | $145.5 | -19% |
| 2025 | $145.5 | $166.2 | +14% |
| 2026 YTD | $166.2 | $166.5 | +0.2% |
RGEN has finished higher in four of the last six years. It's roughly flat so far in 2026.